Update on HIV Preexposure Prophylaxis: Effectiveness, Drug Resistance, and Risk Compensation.

ABSTRACT:

Purpose of review

In 2019, the US government launched an initiative to decrease new HIV infections by 90% over the next decade. Studies have demonstrated the efficacy of HIV preexposure prophylaxis (PrEP) for high-risk populations, and the United States Preventative Services Task Force has issued a grade A recommendation for PrEP, indicating substantial net benefit. However, questions have been raised about the effectiveness of PrEP in clinical settings and whether PrEP use might promote antiretroviral drug resistance and increased sexual risk behaviors, which could increase transmission of bacterial sexually transmitted infections. In this narrative review, we summarize recent evidence of the effectiveness of PrEP when provided in clinical and community settings, the emergence of

SUBMITTER: Powell VE 

PROVIDER: S-EPMC8635937 | biostudies-literature | 2019 Jun

REPOSITORIES: biostudies-literature